Work

Immune and Clinical Outcomes in Patients with Stage IV Melanoma Vaccinated with Peptide-Pulsed Dendritic Cells Derived From CD34+ Progenitors and Activated with Type I Interferon

Year: 2005

Type: article

Study design: Clinical Trial

Source: Journal of Immunotherapy

DOI: 10.1097/01.cji.0000171292.79663.cb

Authors: Jacques Banchereau, Hideki Ueno, Madhav Dhodapkar, John Connolly, Jennifer P Finholt, Eynav Klechevsky, Jean-Philippe Blanck, Dennis A Johnston, A Karolina Palucka, Joseph Fay

Institutions: Memorial Sloan Kettering Cancer Center, Rockefeller University, Technion – Israel Institute of Technology, Baylor University

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, National Cancer Institute

Awards: G1375423453, G3078238047, G3206968062, Improving the Efficacy of Dendritic Cell Vaccines, Subpopulations of Human Dendritic Cells, Anti-tumor Immunity in Myeloma

OpenAlex ID: W2047377397

FWCI: 5.474

Cites: 51

Cited by: 131

Related to: 10